CD8A and cancer: To investigate the effects of PD-L1 blockade on overall T cell responses during cancer immunotherapy, we performed a mass cytometry-based analysis of CD8+ T cells derived from PBMCs from a cohort of 14 NSCLC patients treated with atezolizumab.